These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1280460)

  • 21. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
    J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
    Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
    Cooper IA; Wolf MM; Robertson TI; Fox RM; Matthews JP; Stone JM; Ding JC; Dart G; Matthews J; Firkin FC
    J Clin Oncol; 1994 Apr; 12(4):769-78. PubMed ID: 7512131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MACOP-B regimen in non-Hodgkin's lymphoma.
    Joensuu H; Turpeenniemi-Hujanen T
    Acta Oncol; 1992; 31(6):657-61. PubMed ID: 1281651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
    Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
    Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [NEO-MACOP-B chemotherapy for the treatment of advanced-stage aggressive non-Hodgkin's lymphoma].
    Kohda K; Tsuji A; Takayanagi N; Takeda M; Hayashi S; Takimoto R; Fujisaki Y; Tsuji Y; Ezoe A; Nakazawa O
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2183-9. PubMed ID: 7694548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
    Cameron DA; White JM; Proctor SJ; Prescott RJ; Leonard RC; Angus B; Cook MK; Dawes PJ; Dawson AA; Evans RG; Galloway MJ; Harris AL; Heppleston A; Horne CH; Krajewski AS; Lennard AL; Lessells AM; Lucraft HH; MacGillivray JB; Mackie MJ; Parker AC; Roberts JT; Taylor PR; Thompson WD
    Eur J Cancer; 1997 Jul; 33(8):1195-201. PubMed ID: 9301442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
    Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
    Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
    Wolf M; Matthews JP; Stone J; Cooper IA; Robertson TI; Fox RM
    Ann Oncol; 1997; 8 Suppl 1():71-5. PubMed ID: 9187435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
    Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
    Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
    Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
    Bartlett NL; Kwak LW; Horning SJ
    Cancer; 1993 Jun; 71(12):4034-42. PubMed ID: 7685238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
    Gemmati D; Ongaro A; Tognazzo S; Catozzi L; Federici F; Mauro E; Della Porta M; Campioni D; Bardi A; Gilli G; Pellati A; Caruso A; Scapoli GL; De Mattei M
    Haematologica; 2007 Apr; 92(4):478-85. PubMed ID: 17488658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study.
    Weick JK; Dahlberg S; Fisher RI; Dana B; Miller TP; Balcerzak SP; Pierce HI
    J Clin Oncol; 1991 May; 9(5):748-53. PubMed ID: 1707955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.